Li X, Tibenda JJ, Nan Y, Huang SC, Ning N, Chen GQ, Du YH, Yang YT, Meng FD, Yuan L. MiR-204-3p overexpression inhibits gastric carcinoma cell proliferation by inhibiting the MAPK pathway and RIP1/MLK1 necroptosis pathway to promote apoptosis. World J Gastroenterol 2023; 29(29): 4542-4556 [PMID: 37621755 DOI: 10.3748/wjg.v29.i29.4542]
Corresponding Author of This Article
Ling Yuan, PhD, Professor, College of Pharmacy, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080017@nxmu.edu.cn
Research Domain of This Article
Cell Biology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 7, 2023; 29(29): 4542-4556 Published online Aug 7, 2023. doi: 10.3748/wjg.v29.i29.4542
MiR-204-3p overexpression inhibits gastric carcinoma cell proliferation by inhibiting the MAPK pathway and RIP1/MLK1 necroptosis pathway to promote apoptosis
Xia Li, Joanna J Tibenda, Yi Nan, Shi-Cong Huang, Na Ning, Guo-Qing Chen, Yu-Hua Du, Ya-Ting Yang, Fan-Di Meng, Ling Yuan
Xia Li, Joanna J Tibenda, Shi-Cong Huang, Na Ning, Guo-Qing Chen, Yu-Hua Du, Ling Yuan, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Xia Li, Ningxia Chinese Medicine Reserch Center, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Yi Nan, Fan-Di Meng, Key Laboratory of Hui Ethnic Medicine Modernization of Ministry of Education, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Yi Nan, Ya-Ting Yang, Traditional Chinese Medicine College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Author contributions: Li X carried out most of the studies, analyzed the data, and wrote the manuscript; Nan Y designed the study and revised the manuscript; Tibenda JJ, Du YH and Huang SC wrote the manuscript, and conducted the chart-making work; Ning N and Chen GQ were responsible for the total transcriptomic; Yang YT and Meng FD performed parts of the in vivo and in vitro experiments, and conducted statistical analysis of the data; Yuan L and Nan Y provided the conceptual and technical guidance and revised the manuscript critically for important intellectual content; all authors have read and approved the manuscript.
Institutional review board statement: This manuscript does not involve human experiments.
Institutional animal care and use committee statement: The animal study protocol was approved by the Institutional Animal Care and Use Committee of Ningxia Medical University, No. IACUC-NYLAC-2022-251.
Conflict-of-interest statement: All authors declare no financial or commercial conflict of interest for this article. This article was published during the period of Ling Yuan granted "Young Scholars of Western China"(Class A)_West Light Foundation of the Chinese Academy of Sciences.
Data sharing statement: All data generated or analyzed during this study are included in this paper, and further inquiries can be directed to the corresponding author (E-mail: 20080017@nxmu.edu.cn).
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ling Yuan, PhD, Professor, College of Pharmacy, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080017@nxmu.edu.cn
Received: May 6, 2023 Peer-review started: May 6, 2023 First decision: May 17, 2023 Revised: May 24, 2023 Accepted: July 5, 2023 Article in press: July 5, 2023 Published online: August 7, 2023 Processing time: 87 Days and 17.7 Hours
ARTICLE HIGHLIGHTS
Research background
Gastric carcinoma (GC) is a common gastrointestinal malignancy worldwide. Based on the cancer-related mortality, the current prevention and treatment strategies for GC still show poor clinical results. Therefore, it is important to find effective treatment targets.
Research motivation
At present, the main treatment for GC is surgery, chemotherapy and radiotherapy, but the therapeutic effect is not ideal.
Research objectives
To explore the effect of miR-204-3p on GC cells.
Research methods
We determined the expression level of miR-204-3p in GC, and then used an miR-204-3p overexpression vector and an miR-204-3p knockdown vector in GC cells. The influence of miR-204-3p on the changes in cell phenotype and tumorigenicity in vivo was assessed. Furthermore, the effects of miR-204-3p on various proteins related to the MAPK signaling pathway, necroptosis signaling pathway and apoptosis signaling pathway in GC cells were investigated.
Research results
It was found that miR-204-3p was underexpressed in GC, and miR-204-3p overexpression inhibited GC cell viability, promoted cell apoptosis, blocked the cell cycle, inhibited colony formation ability and inhibited tumorigenicity in vivo. It was also verified that miR-204-3p overexpression can promote apoptosis by inhibiting the MAPK pathway and the necroptosis pathway, thus inhibiting GC cell proliferation.
Research conclusions
MiR-204-3p overexpression inhibited GC cell proliferation by inhibiting the MAPK pathway and the necroptosis pathway to promote GC cell apoptosis.
Research perspectives
MiR-204-3p can be used for targeted therapy of GC, and can also be used as a new biomarker for GC.
